Privia Health Group, Inc. (NASDAQ:PRVA - Get Free Report) has earned an average rating of "Buy" from the thirteen research firms that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation, eleven have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $27.77.
A number of equities research analysts have weighed in on the company. JMP Securities restated a "market outperform" rating and set a $29.00 price objective on shares of Privia Health Group in a research note on Monday, April 28th. Needham & Company LLC restated a "buy" rating and set a $30.00 price objective on shares of Privia Health Group in a research note on Thursday, April 10th. Robert W. Baird raised their price objective on Privia Health Group from $24.00 to $26.00 and gave the company an "outperform" rating in a research note on Tuesday, April 15th. Truist Financial raised their price objective on Privia Health Group from $27.00 to $28.00 and gave the company a "buy" rating in a research note on Thursday, April 10th. Finally, JPMorgan Chase & Co. raised their price objective on Privia Health Group from $29.00 to $32.00 and gave the company an "overweight" rating in a research note on Wednesday, May 28th.
Check Out Our Latest Stock Analysis on PRVA
Insider Buying and Selling
In other news, CEO Parth Mehrotra sold 15,100 shares of the company's stock in a transaction dated Wednesday, April 30th. The stock was sold at an average price of $23.33, for a total transaction of $352,283.00. Following the completion of the sale, the chief executive officer now owns 454,281 shares in the company, valued at approximately $10,598,375.73. This represents a 3.22% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO David Mountcastle sold 5,630 shares of the company's stock in a transaction dated Wednesday, April 2nd. The stock was sold at an average price of $22.38, for a total value of $125,999.40. Following the sale, the chief financial officer now owns 179,676 shares of the company's stock, valued at approximately $4,021,148.88. This trade represents a 3.04% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 51,579 shares of company stock worth $1,226,367 in the last three months. 10.70% of the stock is currently owned by insiders.
Institutional Trading of Privia Health Group
Several hedge funds have recently added to or reduced their stakes in PRVA. Barclays PLC boosted its stake in Privia Health Group by 240.3% during the 3rd quarter. Barclays PLC now owns 224,018 shares of the company's stock valued at $4,079,000 after purchasing an additional 158,188 shares during the period. KBC Group NV boosted its stake in Privia Health Group by 48.1% during the 4th quarter. KBC Group NV now owns 5,012 shares of the company's stock valued at $98,000 after purchasing an additional 1,627 shares during the period. Choreo LLC boosted its stake in Privia Health Group by 8.7% during the 4th quarter. Choreo LLC now owns 21,841 shares of the company's stock valued at $425,000 after purchasing an additional 1,752 shares during the period. Rhumbline Advisers boosted its stake in Privia Health Group by 1.3% during the 4th quarter. Rhumbline Advisers now owns 287,200 shares of the company's stock valued at $5,615,000 after purchasing an additional 3,658 shares during the period. Finally, Peregrine Capital Management LLC boosted its stake in Privia Health Group by 1.8% during the 4th quarter. Peregrine Capital Management LLC now owns 320,768 shares of the company's stock valued at $6,271,000 after purchasing an additional 5,759 shares during the period. Institutional investors own 94.48% of the company's stock.
Privia Health Group Price Performance
NASDAQ PRVA opened at $23.19 on Friday. The company has a 50-day moving average of $23.36 and a 200-day moving average of $22.77. The company has a market cap of $2.83 billion, a P/E ratio of 231.92, a P/E/G ratio of 3.47 and a beta of 0.83. Privia Health Group has a 12 month low of $16.37 and a 12 month high of $26.09.
Privia Health Group Company Profile
(
Get Free ReportPrivia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Privia Health Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Privia Health Group wasn't on the list.
While Privia Health Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.